Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LIPC | P11150 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MTOR | P42345 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359832 | 0.83 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18877293 | 0.73 | ALDH1A1 (0.35) | LMNA | |
| SCHEMBL15075449 | 0.73 | LMNA (0.36) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15075448 | 0.72 | LMNA (0.37) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17359537 | 0.71 | LMNA (0.51) | L3MBTL1LMNATHRBMTORMDM2 | |
| SCHEMBL15074344 | 0.70 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL16492179 | 0.70 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL16377117 | 0.70 | LMNA (0.35) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL17000896 | 0.69 | L3MBTL1 (0.39) | L3MBTL1LMNATHRBMTORMDM2 | |
| SCHEMBL15075447 | 0.69 | PDE4D (0.35) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366888-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | L3MBTL1 1476/4885LIPC 1547/4885LIPG 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.